Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and ...

ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a press ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker. The drug, called evorpacept, is in a pair of phase 2 trials for ...

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...

The inducement stock option has an exercise price of $1.68 per share, which is equal to the closing price of a share of ALX Oncology common stock on the grant date, and vests as follows: 25% of the ...

ALX Oncology reported positive interim results from a phase 2 study of a combo drug featuring evorpacept. Evorpacept showed great potential in treating gastric/gastroesophageal junction cancer. The ...

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies ...

ALX Oncology sees a future for its beleaguered anti-CD47 drug in solid tumors. The biotech reported a 52% response rate in recipients of the therapy, compared to 22% in the control arm, leading it to ...